Table 2.

Univariate Survival Analyses for Key Clinical and Molecular Features. Whilst Clinical Features were Defined for Analysis Prospectively, the Additional Molecular Analyses were Post hoc

		n	EFS (95% CI)		Hazard Ratio (95% CI)	P	OS (95% CI)		Hazard Ratio (95% CI)	P
			5 Year	10 Year			5 Year	10 Year
Whole Cohort		74	49.5 (39.3–62.4)	46.7 (36.5–59.7)			69.3 (59.4–80.9)	60.5 (50.1–73.1)
Resection	GTR	33	69.1 (54.9–87.1)	62.9 (48.2–82.0)	1	.003	81.3 (68.9–96.0)	68.0 (53.4–86.6)	1	.071
	STR	41	33.8 (22.0–52.0)	33.8 (22.0–52.0)	2.6 (1.4–5.1)		59.5 (45.9–77.0)	54.3 (40.7–72.4)	2.0 (0.93–4.2)
WHO Grade	2	39	59.0 (45.4–76.6)	56.4 (42.8–74.3)	1	.061	84.2 (73.3–96.6)	78.8 (66.7–93.0)	1	.005
	3	35	38.7 (25.2–59.2)	35.4 (22.4–56.1)	1.8 (0.96–3.3)		52.2 (37.7–72.3)	39.9 (26.2–60.7)	2.8 (1.3–5.8)
Location	PF	47	55.3 (42.8–71.5)	51.1 (38.6–67.6)	1	.178	69.6 (57.5–84.3)	62.9 (50.3–78.6)	1	.585
	ST	27	38.8 (23.8–63.3)	38.8 (23.8–63.3)	1.5 (0.82–2.8)		68.5 (52.5–89.3)	55.6 (39.0–79.3)	1.2 (0.59–2.5)
1q Status	Gain	18	33.3 (17.3–64.1)	22.2 (9.4–52.7)	1	.003	55.6 (36.8–84.0)	44.4 (26.5–74.5)	1	.042
	No Gain	42	59.0 (45.7–76.1)	59.0 (45.7–76.1)	0.37 (0.19–0.74)		75.5 (64.4–90.0)	68.0 (55.0–84.0)	0.45 (0.21–0.99)
H3K27me3	Positive	22	67.6 (50.5–90.6)	62.8 (45.3–80.7)	1	.165	90.2 (78.2–100)	85.2 (71.1–100)	1	.003
	Negative	32	40.6 (26.7–61.8)	37.5 (24.0–58.7)	1.72 (0.77–3.9)		46.9 (32.4–67.8)	40.6 (26.7–61.8)	4.6 (1.5–13.2)
hTERT	Negative	6	83.3 (58.3–100)	66.7 (37.9–100)	1	.014	100	83.3 (58.3–100)	1	.092
	Positive	10	20.0 (5.8–69.1)	20.0 (5.8–69.1)	5.8 (1.2–28)		50.0 (26.9–92.9)	40.0 (18.7–85.5)	5.2 (0.62–43)

Abbreviations: GTR, Gross Total Resection; STR, Subtotal Resection; PF, Posterior Fossa; ST: Supratentorial; CI, Confidence Interval; EFS: Event Free Survival; OS, Overall Survival.